Skip to content
Screener

Amphastar Pharmaceuticals AMPH Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$191.8MBeat by $1.4M
EPS$0.93Beat by $0.16
Revenue estimate$190.5M
EPS estimate$0.77

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$197.9M
EPS estimate$0.86

Financials

Q3 2025

Income statement

See full
Revenue$191.8M+0.3%
Gross profit$98.6M-3.2%
Operating income$25.3M-55.6%
Net income$17.4M-57.1%
EPS (diluted)$0.37-52.6%

Balance sheet

See full
Cash & equivalents$216.3M+12.6%
Total debt$657.1M+4.2%
Total assets$1.7B+7.8%

Cash flow

See full
Operating cash flow$52.6M-12.3%
CapEx$5.3M-61.2%
Free cash flow$47.2M+2.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.24B-47.9%
Enterprise value$1.68B-40.3%
P/E11.1×-4.0×
P/S1.7×-1.6×

Profitability

See full
Gross margin49.4%-3.6pp
Operating margin20.7%-8.9pp
Net margin15.4%-6.4pp
FCF margin15.7%-7.9pp

Returns & leverage

See full
Current ratio3.1×-0.3×

Segments

By geography

See full
US$180.3M-3.3%
FR$9.7M+114%
CN$1.9M+956%

By segment

See full
Finished Pharmaceutical Products$191.8M+0.3%

FAQ

When did Amphastar Pharmaceuticals report Q3 2025 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Amphastar Pharmaceuticals's Q3 2025 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $191.8M and eps of $0.93 for Q3 2025.
Did Amphastar Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $190.5M by $1.4M. EPS beat the consensus estimate of $0.77 by $0.16.
How did Amphastar Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.6% from $188.8M a year earlier and eps declined 3.1% from $0.96.
Where can I find Amphastar Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001297184-25-000062) and the 10-Q periodic report (0001297184-25-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.